Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts.
Diastolic dysfunction
Heart failure
Left ventricular hypertrophy
Proteomics
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
revised:
16
09
2024
received:
02
07
2024
accepted:
06
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
aheadofprint
Résumé
Biomarkers associated with asymptomatic ventricular dysfunction might improve risk stratification and identify pathways leading to heart failure (HF). We explored the association between proteomic biomarkers and left ventricular hypertrophy (LVH), diastolic dysfunction (DD) and incident HF in three population-based cohorts. A chip was used to measure 92 protein biomarkers in blood samples from >1500 Malmö Preventive Project (MPP) participants, of whom 514 had LVH (34%), 462 had DD (32.4%) and, over a median follow-up of 13 (11-14) years, 130 developed HF (7.7%). Findings were confirmed in the STANISLAS (n > 1500, 238 participants with LVH, 76 with DD) and HOMAGE case-control (562 cases of incident HF, 871 controls) cohorts. In multivariable logistic or Cox regression analyses adjusted for age, sex and cardiovascular risk factors, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was associated with LVH, DD and incident HF in all cohorts: MPP (LVH odds ratio [OR] [95% confidence interval] 1.48 [1.28-1.71]; DD OR 1.71 [1.53-1.92]; HF HR 1.98 [1.66-2.36]); STANISLAS (LVH OR 1.20 [1.02-1.41]; DD OR 1.46 [1.12-1.90]); HOMAGE (HF HR 1.85 [1.62-2.12]). Galectin-4, growth differentiation factor 15 and suppression of tumorigenicity-2 were associated with incident HF in MPP and HOMAGE. A pathway enrichment analysis suggested that inflammation and viral infection were related to incident HF. In conclusion, our study reinforces the role of NT-proBNP as a key biomarker for asymptomatic cardiac dysfunction and incident HF, consistent with its established use in clinical practice. This underscores the value of NT-proBNP for identifying patients at high risk for HF, and provides insights into pathways leading to HF and potential therapeutic targets.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Hjärt-Lungfonden
ID : 2004045806
Organisme : Region Skåne
Organisme : Merck, Sharp & Dohme
Organisme : Hulda och E Conrad Mossfelts Stiftelse för Vetenskaplig Forskning Inom Hjärt- och Kärlsjukdomarnas Område
Organisme : Ernhold Lundströms stiftelse
Organisme : Medicinska Fakulteten, Lunds Universitet
Organisme : Skånes universitetssjukhus
Organisme : Craaford Foundation
Organisme : The Wallenberg Center for Molecular Medicine
Organisme : Swedish Research Council
Organisme : Lunds Universitet
Organisme : Aase og Ejnar Danielsens Fond
Informations de copyright
© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Cleland JGF, Pfeffer MA, Clark AL, Januzzi JL, McMurray JJV, Mueller C, et al. The struggle towards a universal definition of heart failure‐how to proceed? Eur Heart J 2021;42:2331–2343. https://doi.org/10.1093/eurheartj/ehab082
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. https://doi.org/10.1002/ejhf.2333
Echouffo‐Tcheugui JB, Erqou S, Butler J, Yancy CW, Fonarow GC. Assessing the risk of progression from asymptomatic left ventricular dysfunction to overt heart failure: A systematic overview and meta‐analysis. JACC Heart Fail 2016;4:237–248. https://doi.org/10.1016/j.jchf.2015.09.015
Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: The MESA (Multi‐Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008;52:2148–2155. https://doi.org/10.1016/j.jacc.2008.09.014
Shimada YJ, Raita Y, Liang LW, Maurer MS, Hasegawa K, Fifer MA, et al. Comprehensive proteomics profiling reveals circulating biomarkers of hypertrophic cardiomyopathy. Circ Heart Fail 2021;14:e007849. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007849
Ferreira JP, Verdonschot J, Collier T, Wang P, Pizard A, Bär C, et al. Proteomic bioprofiles and mechanistic pathways of progression to heart failure. Circ Heart Fail 2019;12:e005897. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005897
Girerd N, Levy D, Duarte K, Ferreira JP, Ballantyne C, Collier T, et al. Protein biomarkers of new‐onset heart failure: Insights from the Heart Omics and Ageing cohort, the Atherosclerosis Risk in Communities study, and the Framingham Heart Study. Circ Heart Fail 2023;16:e009694. https://doi.org/10.1161/CIRCHEARTFAILURE.122.009694
Stenemo M, Nowak C, Byberg L, Sundström J, Giedraitis V, Lind L, et al. Circulating proteins as predictors of incident heart failure in the elderly. Eur J Heart Fail 2018;20:55–62. https://doi.org/10.1002/ejhf.980
Egerstedt A, Berntsson J, Smith ML, Gidlöf O, Nilsson R, Benson M, et al. Profiling of the plasma proteome across different stages of human heart failure. Nat Commun 2019;10:5830. https://doi.org/10.1038/s41467‐019‐13306‐y
Leosdottir M, Willenheimer R, Plehn J, Borgquist R, Gudmundsson P, Harris TB, et al. Myocardial structure and function by echocardiography in relation to glucometabolic status in elderly subjects from 2 population‐based cohorts: A cross‐sectional study. Am Heart J 2010;159:414–420 e414. https://doi.org/10.1016/j.ahj.2009.12.028
Ferreira JP, Girerd N, Bozec E, Mercklé L, Pizard A, Bouali S, et al. Cohort profile: Rationale and design of the fourth visit of the STANISLAS cohort: A familial longitudinal population‐based cohort from the Nancy region of France. Int J Epidemiol 2018;47:395–395j. https://doi.org/10.1093/ije/dyx240
Jacobs L, Efremov L, Ferreira JP, Thijs L, Yang WY, Zhang ZY, et al.; Heart ‘Omics’ in AGEing (HOMAGE) Investigators. Risk for incident heart failure: A subject‐level meta‐analysis from the Heart ‘Omics’ in AGEing (HOMAGE) study. J Am Heart Assoc 2017;6:e005231. https://doi.org/10.1161/JAHA.116.005231
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79–108. https://doi.org/10.1016/j.euje.2005.12.014
Assarsson E, Lundberg M, Holmquist G, Björkesten J, Bucht Thorsen S, Ekman D, et al. Homogenous 96‐plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 2014;9:e95192. https://doi.org/10.1371/journal.pone.0095192
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277–314. https://doi.org/10.1016/j.echo.2016.01.011
Pellicori P, Ferreira JP, Mariottoni B, Brunner‐la Rocca HP, Ahmed FZ, Verdonschot J, et al. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: Rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. Eur J Heart Fail 2020;22:1711–1723. https://doi.org/10.1002/ejhf.1716
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–2200. https://doi.org/10.1093/eurheartj/ehw128
Kobayashi M, Huttin O, Magnusson M, Ferreira JP, Bozec E, Huby AC, et al.; STANISLAS Study Investigators. Machine learning‐derived echocardiographic phenotypes predict heart failure incidence in asymptomatic individuals. JACC Cardiovasc Imaging 2022;15:193–208. https://doi.org/10.1016/j.jcmg.2021.07.004
Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11–21. https://doi.org/10.1002/sim.4085
Cleland JGF, Butler J, Januzzi JL Jr, Pellicori P, McDonagh T. Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: Implications for clinical practice. Eur J Heart Fail 2022;24:678–680. https://doi.org/10.1002/ejhf.2488
Bansal N, Zelnick L, Go A, Anderson A, Christenson R, Deo R, et al. Cardiac biomarkers and risk of incident heart failure in chronic kidney disease: The CRIC (Chronic Renal Insufficiency Cohort) study. J Am Heart Assoc 2019;8:e012336. https://doi.org/10.1161/JAHA.119.012336
Natriuretic Peptides Studies Collaboration; Willeit P, Kaptoge S, Welsh P, Butterworth AS, Chowdhury R, Spackman SA, et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: An individual‐participant‐data meta‐analysis. Lancet Diabetes Endocrinol 2016;4:840–849. https://doi.org/10.1016/S2213‐8587(16)30196‐6
Huelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, et al. PONTIAC (NT‐proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): A prospective randomized controlled trial. J Am Coll Cardiol 2013;62:1365–1372. https://doi.org/10.1016/j.jacc.2013.05.069
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022;79:1757–1780. https://doi.org/10.1016/j.jacc.2021.12.011
Parikh RH, Seliger SL, Christenson R, Gottdiener JS, Psaty BM, deFilippi C. Soluble ST2 for prediction of heart failure and cardiovascular death in an elderly, community‐dwelling population. J Am Heart Assoc 2016;5:e003188. https://doi.org/10.1161/JAHA.115.003188
Lind L, Arnlov J, Sundstrom J. Plasma protein profile of incident myocardial infarction, ischemic stroke, and heart failure in 2 cohorts. J Am Heart Assoc 2021;10:e017900. https://doi.org/10.1161/JAHA.120.017900
Bouwens E, Brankovic M, Mouthaan H, Baart S, Rizopoulos D, van Boven N, et al. Temporal patterns of 14 blood biomarker candidates of cardiac remodeling in relation to prognosis of patients with chronic heart failure – The Bio‐SHiFT study. J Am Heart Assoc 2019;8:e009555. https://doi.org/10.1161/JAHA.118.009555
Molvin J, Jujic A, Melander O, Pareek M, Råstam L, Lindblad U, et al. Proteomic exploration of common pathophysiological pathways in diabetes and cardiovascular disease. ESC Heart Fail 2020;7:4151–4158. https://doi.org/10.1002/ehf2.13036
Murphy SP, Kakkar R, McCarthy CP, Januzzi JL Jr. Inflammation in heart failure: JACC state‐of‐the‐art review. J Am Coll Cardiol 2020;75:1324–1340. https://doi.org/10.1016/j.jacc.2020.01.014
Tschope C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: Current evidence and future directions. Nat Rev Cardiol 2021;18:169–193. https://doi.org/10.1038/s41569‐020‐00435‐x